Genetic and Epigenetic Determinants of Response to Fluorouracil-based Adjuvant Chemotherapy in Patients With Stage III Colorectal Cancer

Inclusion Criteria: 1. Requirements for tumor parameters 1. Histologically confirmed colorectal adenocarcinoma. 2. Stage III disease (any pT, N1-2, M0). 3. Tumors must have been curatively resected (R0). 4. No evidence of residual involved lymph node disease or metastatic disease at the time of registration. 2. Requirements for patient characteristics 1. Patient is ≥ 18 years of age on the day of consenting to the study. 2. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1 at the time of screening. 3. Fertile patients must use effective contraception. 4. Patients must demonstrate ability to understand and the willingness to sign a written informed consent document. 5. Patients must demonstrate ability to complete study questionnaires. 6. Patients must provide written informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow up. 3. Required initial laboratory values 1. Leukocytes ≥ 3,000/mm\^3 2. Absolute neutrophil count ≥ 1,500/mm\^3 3. Platelet count ≥ 100,000/mm\^3 4. Creatinine ≤ 1.5 times upper limit of normal (ULN) 5. Total Bilirubin ≤ 1.5 times ULN 6. Aspartate aminotransferase (AST) ≤ 2.5 times ULN 7. Alanine aminotransferase (ALT) ≤ 2.5 times ULN Exclusion Criteria: 1. Patients with a known history of allergic reactions attributed to compounds of similar chemical or biologic composition to fluorouracil. 2. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection-requiring intravenous antibiotics, or psychological, familial, sociological, or geographical condition that would limit compliance with study requirements 3. Following cardiovascular conditions within the past 6 months: Myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia, cerebrovascular accident or transient ischemic attack, deep vein thrombosis, other significant thromboembolic event. 4. Known human immunodeficiency virus (HIV)-positive patients and those with known hepatitis B or C. 5. Patients with evidence of other primary malignancies within the past 5 years, excluding adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix. 6. Pregnant or nursing.